Stay updated on Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial

Sign up to get notified when there's something new on the Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    Footer updates include adding Revision: v3.3.3 and removing HHS Vulnerability Disclosure and Revision: v3.3.2.
    Difference
    0.1%
    Check dated 2025-12-23T10:19:03.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    Footer Revision updated from v3.3.1 to v3.3.2; no other page content changes detected. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-12-01T17:48:03.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The revision label in the page footer was updated from v3.2.0 to v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-11-24T14:44:58.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The government funding lapse notice on the page was removed. This change affects only the informational banner and does not modify any trial data or essential page functionality.
    Difference
    0.3%
    Check dated 2025-11-17T06:54:58.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Summary
    The latest version adds new study sites under Contacts/Locations and updates the recruitment status.
    Difference
    0.0%
    Check dated 2025-11-03T01:20:00.000Z thumbnail image
  8. Check
    81 days ago
    Change Detected
    Summary
    - Added a prominent notice about potential outages due to lapse in government funding and updated operating status guidance. - Updated version from v3.1.0 to v3.2.0.
    Difference
    8%
    Check dated 2025-10-05T10:09:31.000Z thumbnail image

Stay in the know with updates to Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial page.